The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
EMA grants gilteritinib regulatory review for the treatment of patients with relapsed/refractory FLT3-positive acute myeloid leukemia
On 1 March 2019, the European Medicines Agency (EMA) accepted a marketing authorization application and granted regulatory review to gilteritinib, a potent, oral fms-like tyrosine kinase 3 (FLT3) inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) FLT3-positive acute myeloid leukemia (AML).1 This comes after gilteritinib received FDA approval for the treatment of patients with FLT3-positive R/R AML in November 2018.
The marketing authorization application is based on the results from the randomized phase III ADMIRAL study (NCT02421939), which is assessing the efficacy of oral gilteritinib vs salvage chemotherapy in adult patients with FLT3-positive R/R AML. Interim results from the trial demonstrated a complete remission/complete remission with partial hematologic recovery rate of 21%.2 The results from the ADMIRAL trial are to be presented at the American Association for Cancer Research Annual Meeting 2019, Atlanta, USA, in March 2019.
According to the drug manufacturers, the marketing authorization application for gilteritinib to the EMA received accelerated assessment, which could result in a shorter timeframe for approval from the Committee for Medicinal Products for Human Use.
References